Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics, LABS Partner on Genetic Testing

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – LABS and Ambry Genetics today announced a deal for the provision of testing services in reproductive health.

The deal, which the two firms said will result in services being available to a wider client base, will make Ambry the preferred provider of genetic carrier screening for LABS. Under the terms of the deal, LABS' customers will be able to access AmbryScreen, a genetic screen for identifying carriers of severe and common childhood diseases affecting pan-ethnic populations, the companies said in a joint statement.

"This partnership brings two premier laboratories together to offer new donor and patient screening options combined with an elite level of service that is unparalleled in the reproductive health industry," Elizabeth Hearty, CEO of LABS, said in the statement. "Ambry also brings to the table strong innovation and cutting-edge technologies within the genetic diagnostic market and that will effectively serve our clients."

Financial and other terms of the deal were not disclosed.

Ambry, based in Aliso Viejo, Calif., is a CLIA-certified specialty laboratory focused on genetic testing and diagnostic services. LABS is a transplant medicine reference laboratory headquartered in Centennial, Colo.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.